Viemed Healthcare (NASDAQ:VMD) Given New $10.00 Price Target at Freedom Broker

Viemed Healthcare (NASDAQ:VMD) had its target price reduced by investment analysts at Freedom Broker from $11.00 to $10.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a “hold” rating on the stock. Freedom Broker‘s target price indicates a potential upside of 11.67% from the stock’s current price.

A number of other equities analysts have also recently weighed in on the stock. Barrington Research assumed coverage on shares of Viemed Healthcare in a research report on Monday, August 24th. They issued an “outperform” rating and a $14.00 price objective for the company. Freedom Capital lowered Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Weiss Ratings downgraded Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 17th. One research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Viemed Healthcare presently has an average rating of “Hold” and a consensus price target of $12.00.

Viemed Healthcare Stock Down 1.9%

Shares of VMD traded down $0.17 during mid-day trading on Monday, reaching $8.96. 195,970 shares of the stock traded hands, compared to its average volume of 284,573. The firm has a market cap of $339.33 million, a price-to-earnings ratio of 23.51, a P/E/G ratio of 2.21 and a beta of 1.05. The stock has a fifty day simple moving average of $9.26 and a 200 day simple moving average of $9.59. Viemed Healthcare has a 12-month low of $6.18 and a 12-month high of $12.61. The company has a quick ratio of 1.16, a current ratio of 1.25 and a debt-to-equity ratio of 0.05.

Viemed Healthcare (NASDAQ:VMD) last posted its earnings results on Wednesday, November 4th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). The firm had revenue of $80.67 million for the quarter, compared to analyst estimates of $80.78 million. Viemed Healthcare had a return on equity of 10.64% and a net margin of 5.03%. Sell-side analysts expect that Viemed Healthcare will post 0.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Viemed Healthcare

Large investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Viemed Healthcare in the second quarter worth $54,587,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Viemed Healthcare by 101.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 711,186 shares of the company’s stock worth $6,550,000 after buying an additional 358,863 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Viemed Healthcare in the 2nd quarter worth about $7,209,873. Punch & Associates Investment Management Inc. bought a new position in shares of Viemed Healthcare in the 2nd quarter worth about $6,082,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Viemed Healthcare by 0.3% in the 1st quarter. Renaissance Technologies LLC now owns 442,200 shares of the company’s stock valued at $4,073,000 after buying an additional 1,400 shares during the period. Institutional investors own 74.24% of the company’s stock.

About Viemed Healthcare

Viemed Healthcare, Inc (NASDAQ: VMD) is a U.S. healthcare company that provides in-home medical equipment and clinical services for patients with chronic respiratory and other complex medical conditions. Its services are designed to help patients receive care at home while supporting hospitals and clinicians in managing ongoing conditions.

The company’s offerings include non-invasive ventilation, oxygen therapy, sleep-apnea equipment, respiratory therapy, remote patient monitoring and related durable medical equipment.